RMC-5552 Monotherapy in Adult Subjects With Recurrent Glioblastoma
Status:
Not yet recruiting
Trial end date:
2025-12-31
Target enrollment:
Participant gender:
Summary
This phase I/Ib trial tests the side effects, best dose, tolerability, and effectiveness of
RMC-5552 in treating patients with glioblastoma that has come back (recurrent). RMC-5552 is a
type of medicine called an mechanistic target of rapamycin (mTOR) inhibitor. These types of
drugs prevent the formation of a specific group of proteins called mTOR. This protein
controls cancer cell growth, and the study doctors believe stopping mTOR from forming may
help to kill tumor cells.
Phase:
Phase 1
Details
Lead Sponsor:
Nicholas Butowski
Collaborators:
National Cancer Institute (NCI) Revolution Medicines, Inc.